Selumetinib (BioDeep_00000229504)
human metabolite
代谢物信息卡片
5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboximidic acid
化学式: C17H15BrClFN4O3 (456.00000220000004)
中文名称: 司美替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
InChI: InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EE - Mitogen-activated protein kinase (mek) inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C69145 - Mitogen-Activated Protein Kinase Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
同义名列表
11 个代谢物同义名
5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboximidic acid; 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-1,3-benzodiazole-5-carboximidic acid; Selumetinib (AZD6244); Selumetinibum; ARRY-142886; ARRY 142886; Selumetinib; ARRY142886; AZD 6244; AZD-6244; AZD6244
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:90227
- PubChem: 10127622
- HMDB: HMDB0304858
- DrugBank: DB11689
- ChEMBL: CHEMBL1614701
- Wikipedia: Selumetinib
- chemspider: 8303141
- CAS: 606143-52-6
- medchemexpress: HY-50706
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Dongdong Zhang, Tieying Zhang, Jianbo Zhu, Jin Li. Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation.
Journal of molecular modeling.
2022 May; 28(6):138. doi:
10.1007/s00894-022-05132-9. [PMID: 35523987] - Yelin Song, Jie Yu, LingLing Li, Lei Wang, Liangle Dong, Guangmin Xi, Yun Jing Lu, Zuowei Li. Luteolin impacts deoxyribonucleic acid repair by modulating the mitogen-activated protein kinase pathway in colorectal cancer.
Bioengineered.
2022 04; 13(4):10998-11011. doi:
10.1080/21655979.2022.2066926. [PMID: 35473479] - Sarit Cohen-Rabbie, Alexandra Mattinson, Karen So, Nan Wang, Ronald Goldwater. Effect of food on capsule and granule formulations of selumetinib.
Clinical and translational science.
2022 04; 15(4):878-888. doi:
10.1111/cts.13209. [PMID: 35170228] - Sarit Cohen-Rabbie, Li Zhou, Karthick Vishwanathan, Martin Wild, Sherrie Xu, Tomoko Freshwater, Lokesh Jain, Stein Schalkwijk, Helen Tomkinson, Diansong Zhou. Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Journal of clinical pharmacology.
2021 11; 61(11):1493-1504. doi:
10.1002/jcph.1935. [PMID: 34196005] - Stein Schalkwijk, Li Zhou, Sarit Cohen-Rabbie, Lokesh Jain, Tomoko Freshwater, Karen So, Zhongqing He, Ioanna Gioni, Helen Tomkinson, Karthick Vishwanathan, Diansong Zhou. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Cancer chemotherapy and pharmacology.
2021 08; 88(2):189-202. doi:
10.1007/s00280-021-04274-6. [PMID: 33903938] - Leonardo C de Oliveira, Aryádina M Ribeiro, Jonas D Albarnaz, Alice A Torres, Luís F Z Guimarães, Amelia K Pinto, Scott Parker, Konstantin Doronin, James D Brien, Mark R Buller, Cláudio A Bonjardim. The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
Archives of virology.
2020 Mar; 165(3):671-681. doi:
10.1007/s00705-020-04524-7. [PMID: 31942645] - Vijay G Ramakrishnan, Kevin C Miller, Elaine P Macon, Teresa K Kimlinger, Jessica Haug, Sanjay Kumar, Wilson I Gonsalves, S Vincent Rajkumar, Shaji K Kumar. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Haematologica.
2019 10; 104(10):2061-2074. doi:
10.3324/haematol.2018.211110. [PMID: 30846494] - F E Marti Marti, G C Jayson, P Manoharan, J O'Connor, A G Renehan, A C Backen, H Mistry, F Ortega, K Li, K L Simpson, J Allen, J Connell, S Underhill, V Misra, K J Williams, I Stratford, A Jackson, C Dive, M P Saunders. Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.
European journal of cancer (Oxford, England : 1990).
2019 08; 117(?):48-59. doi:
10.1016/j.ejca.2019.04.029. [PMID: 31229949] - Parul Patel, Eleanor Howgate, Paul Martin, David J Carlile, Leon Aarons, Diansong Zhou. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
British journal of clinical pharmacology.
2018 Jan; 84(1):52-63. doi:
10.1111/bcp.13404. [PMID: 28833380] - Yizhou Zeng, Xiaofang Tian, Quan Wang, Weiyang He, Jing Fan, Xin Gou. Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.
Drug design, development and therapy.
2018; 12(?):911-920. doi:
10.2147/dddt.s160557. [PMID: 29719377] - Angela W Dymond, Paul Martin, Karen So, Yifan Huang, Paul Severin, Victoria Holmes, Gabriella Mariani, Thomas Marbury. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
Journal of clinical pharmacology.
2017 05; 57(5):592-605. doi:
10.1002/jcph.848. [PMID: 28019010] - Yun Zou, Jianfeng Wang, Xuejiao Leng, Jiwei Huang, Wei Xue, Jin Zhang, Yiran Huang. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Oncotarget.
2017 Mar; 8(13):20825-20833. doi:
10.18632/oncotarget.15346. [PMID: 28212559] - Bo Wang, Kevin Yao, Andrea F Wise, Ricky Lau, Hsin-Hui Shen, Greg H Tesch, Sharon D Ricardo. miR-378 reduces mesangial hypertrophy and kidney tubular fibrosis via MAPK signalling.
Clinical science (London, England : 1979).
2017 Mar; 131(5):411-423. doi:
10.1042/cs20160571. [PMID: 28053239] - Yang Quan-Jun, Huo Yan, Han Yong-Long, Wan Li-Li, Li Jie, Huang Jin-Lu, Lu Jin, Chen Peng-Guo, Gan Run, Guo Cheng. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Molecular cancer therapeutics.
2017 02; 16(2):334-343. doi:
10.1158/1535-7163.mct-16-0324. [PMID: 27599525] - Angela W Dymond, Karen So, Paul Martin, Yifan Huang, Paul Severin, David Mathews, Eleanor Lisbon, Gabriella Mariani. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
European journal of clinical pharmacology.
2017 Feb; 73(2):175-184. doi:
10.1007/s00228-016-2153-7. [PMID: 27889832] - Eva Dombi, Andrea Baldwin, Leigh J Marcus, Michael J Fisher, Brian Weiss, AeRang Kim, Patricia Whitcomb, Staci Martin, Lindsey E Aschbacher-Smith, Tilat A Rizvi, Jianqiang Wu, Rachel Ershler, Pamela Wolters, Janet Therrien, John Glod, Jean B Belasco, Elizabeth Schorry, Alessandra Brofferio, Amy J Starosta, Andrea Gillespie, Austin L Doyle, Nancy Ratner, Brigitte C Widemann. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
The New England journal of medicine.
2016 12; 375(26):2550-2560. doi:
10.1056/nejmoa1605943. [PMID: 28029918] - Angela W Dymond, Colin Howes, Christine Pattison, Karen So, Gabriella Mariani, Mark Savage, Stuart Mair, Gill Ford, Paul Martin. Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.
Clinical therapeutics.
2016 Nov; 38(11):2447-2458. doi:
10.1016/j.clinthera.2016.09.002. [PMID: 27751676] - Paul Severin, Christopher Bailey, Meng Chen, Ashley Fisher, Victoria Holmes. Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS/MS.
Bioanalysis.
2016 Sep; 8(18):1919-36. doi:
10.4155/bio-2016-0082. [PMID: 27523799] - Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z Badros, Peter M Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle Herrmann, Liqiang Xi, Mark Raffeld, Xiuhua Zhao, Wen Wan, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Heidi Sankala, Kevin T Hogan, Austin Doyle, Christina M Annunziata, Martha Wellons, John D Roberts, Daniel Sullivan, Ola Landgren, Steven Grant. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016 Mar; 22(5):1067-75. doi:
10.1158/1078-0432.ccr-15-1076. [PMID: 26446942] - Andrew H Ko, Tanios Bekaii-Saab, Jessica Van Ziffle, Olga M Mirzoeva, Nancy M Joseph, AmirAli Talasaz, Peter Kuhn, Margaret A Tempero, Eric A Collisson, R Kate Kelley, Alan P Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, W Michael Korn. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016 Jan; 22(1):61-8. doi:
10.1158/1078-0432.ccr-15-0979. [PMID: 26251290] - Aswathi A George, Helicia Paz, Fei Fei, Jonathan Kirzner, Yong-Mi Kim, Nora Heisterkamp, Hisham Abdel-Azim. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
PloS one.
2015; 10(9):e0137917. doi:
10.1371/journal.pone.0137917. [PMID: 26360058] - Silvina Grasso, Elena Tristante, Miguel Saceda, Pablo Carbonell, Leticia Mayor-López, Mar Carballo-Santana, Estefanía Carrasco-García, Lourdes Rocamora-Reverte, Pilar García-Morales, Fernando Carballo, José A Ferragut, Isabel Martínez-Lacaci. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Neoplasia (New York, N.Y.).
2014 Oct; 16(10):845-60. doi:
10.1016/j.neo.2014.08.011. [PMID: 25379021] - Ingo V Hartung, Marion Hitchcock, Florian Pühler, Roland Neuhaus, Arne Scholz, Stefanie Hammer, Kirstin Petersen, Gerhard Siemeister, Dominic Brittain, Roman C Hillig. Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
Bioorganic & medicinal chemistry letters.
2013 Apr; 23(8):2384-90. doi:
10.1016/j.bmcl.2013.02.028. [PMID: 23474388] - Junyao Xu, Jennifer J Knox, Emin Ibrahimov, Eric Chen, Stefano Serra, Ming Tsao, Pinjiang Cao, Douglass Vines, David E Green, Cristiane Metran-Nascente, Mairead G McNamara, David W Hedley. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Jan; 19(1):118-27. doi:
10.1158/1078-0432.ccr-12-2557. [PMID: 23091117] - John Shyi Peng Yuen, Mei Yi Sim, Hong Gee Sim, Tsung Wen Chong, Weber Kam On Lau, Christopher Wai Sam Cheng, Richard Weijie Ong, Hung Huynh. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
International journal of oncology.
2012 Aug; 41(2):712-20. doi:
10.3892/ijo.2012.1494. [PMID: 22641227] - Antoine Muchir, Sarah A Reilly, Wei Wu, Shinichi Iwata, Shunichi Homma, Gisèle Bonne, Howard J Worman. Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene.
Cardiovascular research.
2012 Feb; 93(2):311-9. doi:
10.1093/cvr/cvr301. [PMID: 22068161] - Suzanne Leijen, Patricia M M B Soetekouw, T R Jeffry Evans, Marianne Nicolson, Jan H M Schellens, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2011 Dec; 68(6):1619-28. doi:
10.1007/s00280-011-1732-7. [PMID: 21953275] - Xin-Yan Pei, Yun Dai, Leena E Youssefian, Shuang Chen, Wesley W Bodie, Yukie Takabatake, Jessica Felthousen, Jorge A Almenara, Lora B Kramer, Paul Dent, Steven Grant. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Blood.
2011 Nov; 118(19):5189-200. doi:
10.1182/blood-2011-02-339432. [PMID: 21911831] - Sylwia Ammoun, Marei Caroline Schmid, Joceline Triner, Paul Manley, Clemens Oliver Hanemann. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Neuro-oncology.
2011 Jul; 13(7):759-66. doi:
10.1093/neuonc/nor056. [PMID: 21727212] - Fatima A Saleh, Muna Whyte, Peter Ashton, Paul G Genever. Regulation of mesenchymal stem cell activity by endothelial cells.
Stem cells and development.
2011 Mar; 20(3):391-403. doi:
10.1089/scd.2010.0168. [PMID: 20536359] - Cathrine L Denton, Daniel L Gustafson. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Cancer chemotherapy and pharmacology.
2011 Feb; 67(2):349-60. doi:
10.1007/s00280-010-1323-z. [PMID: 20407895] - Udai Banerji, D Ross Camidge, Henk M W Verheul, Roshan Agarwal, Debashis Sarker, Stan B Kaye, Ingrid M E Desar, Johanna N H Timmer-Bonte, S Gail Eckhardt, Karl D Lewis, Kathryn H Brown, Mireille V Cantarini, Clive Morris, Sarah M A George, Paul D Smith, Carla M L van Herpen. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010 Mar; 16(5):1613-23. doi:
10.1158/1078-0432.ccr-09-2483. [PMID: 20179232] - R E Board, G Ellison, M C M Orr, K R Kemsley, G McWalter, L Y Blockley, S P Dearden, C Morris, M Ranson, M V Cantarini, C Dive, A Hughes. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
British journal of cancer.
2009 Nov; 101(10):1724-30. doi:
10.1038/sj.bjc.6605371. [PMID: 19861964] - Qing Chang, Eric Chen, David W Hedley. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Cancer biology & therapy.
2009 Oct; 8(20):1893-901. doi:
10.4161/cbt.8.20.9430. [PMID: 20009539] - M Staehler, K Rohrmann, N Haseke, C G Stief, M Siebels. Targeted agents for the treatment of advanced renal cell carcinoma.
Current drug targets.
2005 Nov; 6(7):835-46. doi:
10.2174/138945005774574498. [PMID: 16305462]